Generate Investment Management Ltd Acquires 41,472 Shares of AbbVie Inc. $ABBV

Generate Investment Management Ltd increased its holdings in AbbVie Inc. (NYSE:ABBV) by 91.8% in the 3rd quarter, Holdings Channel reports. The fund owned 86,669 shares of the company’s stock after buying an additional 41,472 shares during the quarter. Generate Investment Management Ltd’s holdings in AbbVie were worth $20,067,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Marshall & Sullivan Inc. WA bought a new position in AbbVie during the 2nd quarter valued at approximately $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie in the second quarter worth about $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $39,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ABBV shares. Bank of America raised their price target on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research note on Tuesday, November 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, Scotiabank initiated coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Stock Down 0.5%

Shares of ABBV opened at $229.63 on Wednesday. The stock has a market capitalization of $405.84 billion, a PE ratio of 173.96, a P/E/G ratio of 1.31 and a beta of 0.36. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The company’s 50-day simple moving average is $226.67 and its 200-day simple moving average is $213.27.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is currently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.